XML 27 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Note 17 - Subsequent Events
3 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]
17.
SUBSEQUENT EVENTS
 
Refer to Note
11
for subsequent events related to the conversions of the Amended Note.
 
On
April 2, 2020,
the Company issued
6,850
shares of common stock to its directors in payment of meeting fees. Additionally, the Company issued a stock option to a new employee for
5,000
shares with
three
-year vesting period. 
 
On
April 20, 2020,
the Company entered into a Paycheck Protection Program Term Note (the “SVB Note”) with Silicon Valley Bank (“SVB”) pursuant to the Paycheck Protection Program (the “Program”) of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. The Company received total proceeds of
$340,000
which will be used in accordance with the requirements of the CARES Act.  The Company will apply to SVB for forgiveness of amounts due on the SVB Note to the extent they are used for eligible payroll costs, rent obligations, and covered utility payments incurred during the “covered period” following disbursement under the SVB Note.  Until the
six
-month anniversary of the date of the SVB Note (the “Deferral Expiration Date”), neither principal nor interest is due and payable. On the Deferral Expiration Date, the outstanding principal of the SVB Note that is
not
forgiven will convert to an amortizing term loan at an interest rate of
1%
per annum requiring equal monthly payments of principal and interest through
November 20, 2022. 
While these are the initial guidelines, we are monitoring the announcements for the issuance of the final guidelines.
 
On
May 6, 2020,
the Company issued a
$2,415,000
principal amount senior secured convertible note (the “Note”).  At closing,
$2,100,000
was funded. The principal amount is due and payable in
five
equal monthly installments of
$268,333
beginning
seven
months after the funding date with the remaining balance due on the
twelfth
month after the date of funding. The Note is convertible at a fixed convertible price of
$1.16
per share. In connection with the issuance of the Note, the Company paid a
$133,333
due diligence fee by issuing
114,943
shares to the Investor priced at
$1.16.
The Company also issued a warrant to purchase
1,900,000
shares of common stock at a fixed exercise price of
$1.16
and paid a placement fee of
7%
of the gross proceeds to a placement agent.
 
On
May 12, 2020,
the Company issued
7,077
shares of common stock to its directors in payment of meeting fees.  Additionally, the Company issued a warrant to an investor for
125,000
shares for a business referral. 
 
On
May 14, 2020,
the Company issued
1,632
shares of common stock to its directors in payment of committee meeting fees.
 
Subsequent to period-end, due to the effects of the worldwide coronavirus pandemic, the Company is closely monitoring its operations, liquidity, and capital resources. The COVID-
19
outbreak has caused us to migrate to a remote business model for our sales, marketing, administrative and executive teams.  Research and development and production are adjusting to the new landscape to maintain production as best as possible considering the conditions and regulations. We continue to monitor the situation closely and it is possible that we will implement further measures. Since we qualify as an essential business in New Jersey because we serve the healthcare industry, we have been able to access inventory to fulfill orders and ship products as required. We are actively working to minimize the current and future impact of this unprecedented situation. As of the date of issuance of these financial statements, the full impact to the Company’s financial position is
not
known.
 
The Company has reviewed subsequent events through the date of this filing.